Use of nicorandil is Associated with Increased Risk for Gastrointestinal Ulceration and Perforation-A Nationally Representative Population-based study

Chien Chang Lee, Shy Shin Chang, Shih Hao Lee, Yueh Sheng Chen, Wan Ting Hsu, Meng Tse Gabriel Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Nicorandil is a vasodilatory drug used to relieve angina symptoms. Several healthcare products regulatory agencies have issued a warning associating the use of nicorandil and gastrointestinal (GI) ulceration. We aimed to evaluate the association between use of nicorandil and GI ulceration/perforation. A population-based cohort study involving 1 million randomly sampled participants in Taiwanâ €™ s National Health Insurance Research Database was carried out. We estimated the association between use of nicorandil and GI ulceration/perforation by a Cox proportional hazards regression model. A nicorandil-specific propensity score (PS) was also created for adjustment of 75 covariates and matching. 25.8% (183/710) of nicorandil-treated patients developed new GI ulcer events and 1.6% (20/1254) developed new GI perforation events in the three-year follow-up period, as compared to 9.3% (61,281/659,081) and 0.3% (2,488/770,537) in the general population comparator cohort. Patients treated with nicorandil were at significantly increased risk of GI ulcer (PS adjusted hazard ratio 1.43, 95% CI, 1.23 to 1.65, 6848 excess cases per 100,000 person years) or GI perforation (aHR 1.60, 95% CI 1.02-2.51, 315 excess cases per 100,000 person years) compared with the nicorandil unexposed population. Our finding may warn the clinicians to weigh the overall risk-benefit balance of nicorandil treatment in patients.

Original languageEnglish
Article number11495
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - Jun 29 2015
Externally publishedYes

Fingerprint

Nicorandil
Population
Propensity Score
Ulcer
National Health Programs
Taiwan
Proportional Hazards Models
Cohort Studies
Databases
Delivery of Health Care

ASJC Scopus subject areas

  • General

Cite this

Use of nicorandil is Associated with Increased Risk for Gastrointestinal Ulceration and Perforation-A Nationally Representative Population-based study. / Lee, Chien Chang; Chang, Shy Shin; Lee, Shih Hao; Chen, Yueh Sheng; Hsu, Wan Ting; Gabriel Lee, Meng Tse.

In: Scientific Reports, Vol. 5, 11495, 29.06.2015.

Research output: Contribution to journalArticle

@article{50a9a7e4cac447268e91e039fee683d1,
title = "Use of nicorandil is Associated with Increased Risk for Gastrointestinal Ulceration and Perforation-A Nationally Representative Population-based study",
abstract = "Nicorandil is a vasodilatory drug used to relieve angina symptoms. Several healthcare products regulatory agencies have issued a warning associating the use of nicorandil and gastrointestinal (GI) ulceration. We aimed to evaluate the association between use of nicorandil and GI ulceration/perforation. A population-based cohort study involving 1 million randomly sampled participants in Taiwan{\^a} €™ s National Health Insurance Research Database was carried out. We estimated the association between use of nicorandil and GI ulceration/perforation by a Cox proportional hazards regression model. A nicorandil-specific propensity score (PS) was also created for adjustment of 75 covariates and matching. 25.8{\%} (183/710) of nicorandil-treated patients developed new GI ulcer events and 1.6{\%} (20/1254) developed new GI perforation events in the three-year follow-up period, as compared to 9.3{\%} (61,281/659,081) and 0.3{\%} (2,488/770,537) in the general population comparator cohort. Patients treated with nicorandil were at significantly increased risk of GI ulcer (PS adjusted hazard ratio 1.43, 95{\%} CI, 1.23 to 1.65, 6848 excess cases per 100,000 person years) or GI perforation (aHR 1.60, 95{\%} CI 1.02-2.51, 315 excess cases per 100,000 person years) compared with the nicorandil unexposed population. Our finding may warn the clinicians to weigh the overall risk-benefit balance of nicorandil treatment in patients.",
author = "Lee, {Chien Chang} and Chang, {Shy Shin} and Lee, {Shih Hao} and Chen, {Yueh Sheng} and Hsu, {Wan Ting} and {Gabriel Lee}, {Meng Tse}",
year = "2015",
month = "6",
day = "29",
doi = "10.1038/srep11495",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Use of nicorandil is Associated with Increased Risk for Gastrointestinal Ulceration and Perforation-A Nationally Representative Population-based study

AU - Lee, Chien Chang

AU - Chang, Shy Shin

AU - Lee, Shih Hao

AU - Chen, Yueh Sheng

AU - Hsu, Wan Ting

AU - Gabriel Lee, Meng Tse

PY - 2015/6/29

Y1 - 2015/6/29

N2 - Nicorandil is a vasodilatory drug used to relieve angina symptoms. Several healthcare products regulatory agencies have issued a warning associating the use of nicorandil and gastrointestinal (GI) ulceration. We aimed to evaluate the association between use of nicorandil and GI ulceration/perforation. A population-based cohort study involving 1 million randomly sampled participants in Taiwanâ €™ s National Health Insurance Research Database was carried out. We estimated the association between use of nicorandil and GI ulceration/perforation by a Cox proportional hazards regression model. A nicorandil-specific propensity score (PS) was also created for adjustment of 75 covariates and matching. 25.8% (183/710) of nicorandil-treated patients developed new GI ulcer events and 1.6% (20/1254) developed new GI perforation events in the three-year follow-up period, as compared to 9.3% (61,281/659,081) and 0.3% (2,488/770,537) in the general population comparator cohort. Patients treated with nicorandil were at significantly increased risk of GI ulcer (PS adjusted hazard ratio 1.43, 95% CI, 1.23 to 1.65, 6848 excess cases per 100,000 person years) or GI perforation (aHR 1.60, 95% CI 1.02-2.51, 315 excess cases per 100,000 person years) compared with the nicorandil unexposed population. Our finding may warn the clinicians to weigh the overall risk-benefit balance of nicorandil treatment in patients.

AB - Nicorandil is a vasodilatory drug used to relieve angina symptoms. Several healthcare products regulatory agencies have issued a warning associating the use of nicorandil and gastrointestinal (GI) ulceration. We aimed to evaluate the association between use of nicorandil and GI ulceration/perforation. A population-based cohort study involving 1 million randomly sampled participants in Taiwanâ €™ s National Health Insurance Research Database was carried out. We estimated the association between use of nicorandil and GI ulceration/perforation by a Cox proportional hazards regression model. A nicorandil-specific propensity score (PS) was also created for adjustment of 75 covariates and matching. 25.8% (183/710) of nicorandil-treated patients developed new GI ulcer events and 1.6% (20/1254) developed new GI perforation events in the three-year follow-up period, as compared to 9.3% (61,281/659,081) and 0.3% (2,488/770,537) in the general population comparator cohort. Patients treated with nicorandil were at significantly increased risk of GI ulcer (PS adjusted hazard ratio 1.43, 95% CI, 1.23 to 1.65, 6848 excess cases per 100,000 person years) or GI perforation (aHR 1.60, 95% CI 1.02-2.51, 315 excess cases per 100,000 person years) compared with the nicorandil unexposed population. Our finding may warn the clinicians to weigh the overall risk-benefit balance of nicorandil treatment in patients.

UR - http://www.scopus.com/inward/record.url?scp=84934283938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934283938&partnerID=8YFLogxK

U2 - 10.1038/srep11495

DO - 10.1038/srep11495

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 11495

ER -